@author-1788515151757110
启明创投致力于成为中国优秀技术创业者们的首选投资机构
Qiming Venture Partners remains steadfast in its focus on addressing unmet clinical needs and consistently pursues cutting-edge healthcare innovations with global competitiveness.
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Over the next five to ten years, more highly original R&D breakthroughs are expected to emerge from labs in China and contribute to global pharmaceutical innovation.
The systematic capabilities Qiming Venture Partners has built over nearly two decades: long-term conviction focused on two core sectors, a systematic "half-step ahead" deployment strategy, and full-chain expertise spanning early to growth stages.
Qiming Venture Partners' investment strategy is becoming increasingly focused, staying committed to deepening its existing circle of competence and building out its portfolio with steady, deliberate execution.
As early as 2019, Qiming Venture Partners led Yunyinggu's Series C round and continued to back the company in its subsequent Series D financing.
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
China's most authoritative and influential innovation benchmark for the healthcare industry
Our primary focus is the technology development cycle, and we structure our investments around this cycle as the central thread.
For the next ten years, China will remain the global center of consumer hardware innovation.
